Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 25 vs MANNITOL 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Reduction of elevated intracranial pressure,Promotion of diuresis in acute renal failure,Reduction of intraocular pressure,Adjunct in treatment of acute oliguric renal failure,Management of cerebral edema
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal elimination half-life is 0.25–1.5 hours; prolonged in renal impairment (up to 36 hours).
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Renal: >90% as unchanged drug; minimal biliary or fecal excretion.
97–99% (sex hormone-binding globulin and albumin)
Negligible (<0.1%); no specific binding proteins.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
0.2–0.5 L/kg; primarily confined to extracellular fluid; increases with dehydration.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
IV: 100%; oral: <10% due to poor absorption.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. No specific dose for GFR >50 m L/min.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
No specific dose adjustment for hepatic impairment. Caution in patients with cirrhosis due to risk of fluid overload.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Children: For reduction of intracranial pressure, 0.25-1 g/kg as a 15-25% solution IV over 30-60 minutes. For diuresis, 0.5-2 g/kg as a 5-25% solution IV every 6-12 hours. Maximum dose 2 g/kg/dose.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
Elderly: Use lower doses and titrate carefully due to increased risk of fluid overload, electrolyte disturbances, and renal impairment. Monitor renal function and serum osmolarity. Start with the lower end of adult dosing range.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
None
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
May cause volume expansion and pulmonary edema in patients with impaired renal function. Monitor renal function, serum electrolytes, and fluid balance. Avoid extravasation as it may cause tissue necrosis. Use with caution in patients with congestive heart failure or severe dehydration.
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, known hypersensitivity to mannitol.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
No significant food interactions; maintain adequate hydration unless contraindicated.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First trimester: theoretical risk from osmotic shifts. Second/third trimester: monitor for maternal hemodynamic changes (e.g., pulmonary edema) that may affect placental perfusion.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
Unknown if excreted in human milk. No available data on M/P ratio. Consider benefits of breastfeeding vs. potential risk of osmotic effects or maternal dehydration. Caution advised.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
No specific dose adjustments recommended for pregnancy alone. Consider increased plasma volume in pregnancy; monitor for volume overload. Dose based on clinical response and renal function. Avoid rapid infusion.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Administer via large-bore IV; monitor serum osmolality and renal function; ensure urine output >30 m L/h; avoid extravasation; use with caution in patients with pulmonary congestion or CHF.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
You may experience increased urination during treatment.,Report any chest pain, difficulty breathing, or swelling to your doctor immediately.,You may feel thirsty or have a dry mouth; this is expected.,Your blood sugar levels may be monitored if you have diabetes.,Avoid consuming large amounts of salt or salty foods.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 25 vs MANNITOL 10% IN PLASTIC CONTAINER, answered by our medical review team.
ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. MANNITOL 10% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 25 and MANNITOL 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. The standard adult dose of MANNITOL 10% IN PLASTIC CONTAINER is: Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 25 and MANNITOL 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. MANNITOL 10% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.